On October 2, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics Inc (APGE, Financial), sold 6,665 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 274,128 shares of Apogee Therapeutics Inc.
Apogee Therapeutics Inc is engaged in the development of therapies aimed at treating autoimmune and inflammatory diseases. The company's focus on innovation and targeted treatments positions it as a notable player in the biopharmaceutical sector.
The shares were sold at a price of $56.26 each, valuing the transaction at approximately $375,073.90. This sale is part of a broader trend observed over the past year, where the insider has sold a total of 26,660 shares and made no purchases.
Insider trading trends at Apogee Therapeutics Inc over the last year show no insider purchases but a total of 9 insider sales. This pattern of transactions provides insights into the insider's trading behavior and the company's stock performance.
Currently, Apogee Therapeutics Inc has a market cap of approximately $3.09 billion. The stock's valuation metrics, including the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are essential for investors considering the stock's current and future potential.
For a detailed analysis of the insider's historical trading activities and the company's stock valuation, investors can refer to the GF Value.
This insider sale might be of interest to current and potential investors trying to understand market sentiments and the insider's perspective on the stock's value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
